CY1113191T1 - Συνθεση συμπιεσμενων δισκιων εφαβιρενζης - Google Patents
Συνθεση συμπιεσμενων δισκιων εφαβιρενζηςInfo
- Publication number
- CY1113191T1 CY1113191T1 CY20121100778T CY121100778T CY1113191T1 CY 1113191 T1 CY1113191 T1 CY 1113191T1 CY 20121100778 T CY20121100778 T CY 20121100778T CY 121100778 T CY121100778 T CY 121100778T CY 1113191 T1 CY1113191 T1 CY 1113191T1
- Authority
- CY
- Cyprus
- Prior art keywords
- compacted
- discs
- effective
- composition
- efavirenz
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Η εφεύρεση αφορά μια σύνθεση συμπιεσμένου δισκίου εφαβιρένζης, το οποίο φορτίζεται με 50% κατά βάρος δραστική ουσία. Η εφαβιρένζη είναι ένας μη νουκλεοσιδικός αναστολέας της αντίστροφης τρανσκριπτάσης, ο οποίος μελετάται κλινικά για χρήση εις τη θεραπευτική αγωγή μολύνσεων ΗIV και ΑΙDS.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8692198P | 1998-05-27 | 1998-05-27 | |
GBGB9815800.9A GB9815800D0 (en) | 1998-07-21 | 1998-07-21 | Compressed tablet formulation |
EP03076054A EP1332757B1 (en) | 1998-05-27 | 1999-05-24 | Efavirenz compressed tablet formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1113191T1 true CY1113191T1 (el) | 2016-04-13 |
Family
ID=26314071
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20121100778T CY1113191T1 (el) | 1998-05-27 | 2012-08-29 | Συνθεση συμπιεσμενων δισκιων εφαβιρενζης |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP1083901B1 (el) |
JP (1) | JP4000354B2 (el) |
AT (1) | ATE237332T1 (el) |
AU (1) | AU761182B2 (el) |
CA (1) | CA2332876C (el) |
CO (1) | CO5070643A1 (el) |
CY (1) | CY1113191T1 (el) |
DE (1) | DE69906963D1 (el) |
DK (1) | DK1332757T3 (el) |
ES (1) | ES2388849T3 (el) |
PE (1) | PE20000559A1 (el) |
PT (1) | PT1332757E (el) |
SI (1) | SI1332757T1 (el) |
WO (1) | WO1999061026A1 (el) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA72207C2 (uk) | 1998-04-07 | 2005-02-15 | Брістол- Майєрс Сквібб Фарма Компані | Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення |
CA2311734C (en) * | 2000-04-12 | 2011-03-08 | Bristol-Myers Squibb Company | Flash-melt oral dosage formulation |
WO2003045327A2 (en) * | 2001-11-27 | 2003-06-05 | Bristol-Myers Squibb Company | Efavirenz tablet formulation having unique biopharmaceutical characteristics |
EP1545206B1 (en) | 2002-07-24 | 2020-03-04 | Children's Hospital Medical Center | Compositions and products containing enantiomeric equol, and methods for their making |
WO2004064846A1 (en) | 2003-01-14 | 2004-08-05 | Gilead Sciences, Inc. | Compositions and methods for combination antiviral therapy |
US7198653B2 (en) * | 2003-07-31 | 2007-04-03 | Delavau Llc | Calcium carbonate granulation |
JP2005089396A (ja) * | 2003-09-19 | 2005-04-07 | Pola Chem Ind Inc | イソフラボン含有経口投与組成物 |
TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
US9198862B2 (en) | 2005-07-22 | 2015-12-01 | Rubicon Research Private Limited | Dispersible tablet composition |
US20070059360A1 (en) * | 2005-07-29 | 2007-03-15 | Ashish Jaiswal | Water-dispersible anti-retroviral pharmaceutical compositions |
UA95093C2 (uk) * | 2005-12-07 | 2011-07-11 | Нікомед Фарма Ас | Спосіб одержання кальцієвмісної сполуки |
WO2009026257A2 (en) * | 2007-08-17 | 2009-02-26 | Teva Pharmaceutical Industries Ltd. | Methods and compositions for controlling the bioavailability of poorly soluble drugs |
DE102008047910A1 (de) | 2008-09-19 | 2010-03-25 | Molkerei Meggle Wasserburg Gmbh & Co. Kg | Tablettierhilfsstoff auf Laktose- und Cellulosebasis |
US20110009347A1 (en) | 2009-07-08 | 2011-01-13 | Yin Liang | Combination therapy for the treatment of diabetes |
CN102985072A (zh) | 2010-04-20 | 2013-03-20 | 希普拉有限公司 | 药物组合物 |
PT2568988T (pt) | 2010-05-11 | 2016-09-22 | Janssen Pharmaceutica Nv | Formulações farmacêuticas compreendendo derivados de 1-(beta-d-glucopiranosil)-2-tienilmetilbenzeno como inhibidoras de sglt |
EP2441759A1 (en) | 2010-10-14 | 2012-04-18 | Lonza Ltd. | Process for the synthesis of cyclic carbamates |
EP2447255A1 (en) | 2010-10-14 | 2012-05-02 | Lonza Ltd. | Process for the synthesis of cyclic carbamates |
CA2851862C (en) * | 2011-10-17 | 2020-04-14 | Lexicon Pharmaceutical Inc. | Solid dosage forms of (s)-ethyl 2-amino-3-(4-(2-amino-6-((r)-1-(4-chloro-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate |
CN103508973B (zh) * | 2012-06-25 | 2016-04-27 | 上海迪赛诺药业有限公司 | 制备依非韦伦i型结晶的方法 |
IN2013MU03370A (el) | 2013-10-25 | 2015-09-25 | Cipla Ltd | |
RU2759544C1 (ru) * | 2021-01-29 | 2021-11-15 | Общество с ограниченной ответственностью "АМЕДАРТ" | Твёрдая фармацевтическая композиция для изготовления перорального терапевтического средства для профилактики и/или лечения ВИЧ-инфекции |
CN113499441A (zh) * | 2021-08-05 | 2021-10-15 | 上海合全医药有限公司 | 一种药用糖包衣液及其制备方法 |
CN113999543B (zh) * | 2021-10-29 | 2022-11-04 | 广西华纳新材料股份有限公司 | 一种钙-硅核壳结构纳米碳酸钙的制备方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1694295A (en) * | 1994-01-28 | 1995-08-15 | Merck & Co., Inc. | Benzoxazinones as inhibitors of hiv reverse transcriptase |
US5633405A (en) * | 1995-05-25 | 1997-05-27 | Merck & Co., Inc. | Asymmetric synthesis of (-)-6-chloro-4-cyclopropyl-ethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxanzin-2-one |
AR012702A1 (es) * | 1997-05-17 | 2000-11-08 | Glaxo Group Ltd | Combinacion de (-)-(1s,4r)-4-[2-amino-6-(ciclopropilamino)-9h-purin-9-il]- 2-ciclopenteno-1-metanol y un inhibidor dee transcriptasa reversa no nucleosidouna formulacion farmaceutica que comprende la combinacion, su uso medico en terapia para tratar la infeccion de vih, y un empaque para el paciente |
-
1999
- 1999-05-21 CO CO99031381A patent/CO5070643A1/es unknown
- 1999-05-21 PE PE1999000431A patent/PE20000559A1/es not_active IP Right Cessation
- 1999-05-24 DK DK03076054.0T patent/DK1332757T3/da active
- 1999-05-24 EP EP99925793A patent/EP1083901B1/en not_active Expired - Lifetime
- 1999-05-24 WO PCT/US1999/011464 patent/WO1999061026A1/en active IP Right Grant
- 1999-05-24 SI SI9931069T patent/SI1332757T1/sl unknown
- 1999-05-24 CA CA002332876A patent/CA2332876C/en not_active Expired - Lifetime
- 1999-05-24 AU AU42010/99A patent/AU761182B2/en not_active Expired
- 1999-05-24 AT AT99925793T patent/ATE237332T1/de not_active IP Right Cessation
- 1999-05-24 ES ES03076054T patent/ES2388849T3/es not_active Expired - Lifetime
- 1999-05-24 JP JP2000550486A patent/JP4000354B2/ja not_active Expired - Lifetime
- 1999-05-24 PT PT03076054T patent/PT1332757E/pt unknown
- 1999-05-24 DE DE69906963T patent/DE69906963D1/de not_active Expired - Lifetime
-
2012
- 2012-08-29 CY CY20121100778T patent/CY1113191T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP1083901A1 (en) | 2001-03-21 |
AU761182B2 (en) | 2003-05-29 |
PE20000559A1 (es) | 2000-07-05 |
ES2388849T3 (es) | 2012-10-19 |
JP4000354B2 (ja) | 2007-10-31 |
DE69906963D1 (de) | 2003-05-22 |
PT1332757E (pt) | 2012-09-03 |
CO5070643A1 (es) | 2001-08-28 |
EP1083901B1 (en) | 2003-04-16 |
ATE237332T1 (de) | 2003-05-15 |
SI1332757T1 (sl) | 2012-10-30 |
DK1332757T3 (da) | 2012-09-24 |
JP2002516281A (ja) | 2002-06-04 |
WO1999061026A1 (en) | 1999-12-02 |
CA2332876C (en) | 2008-07-08 |
AU4201099A (en) | 1999-12-13 |
CA2332876A1 (en) | 1999-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1113191T1 (el) | Συνθεση συμπιεσμενων δισκιων εφαβιρενζης | |
AU2003297260A1 (en) | Fast-disintegrating solid dosage forms being not friable and comprising pullulan | |
EP1268412B8 (en) | Sulphonamido-substituted bridged bicycloalkyl derivatives | |
HUP0103883A2 (hu) | Új, késleltetett felszabadulású, orális készítmények | |
BR0107869A (pt) | Composições farmacêuticas eletrogiradas | |
HUP0301868A2 (hu) | Gyógyászati készítmény, ami VIIa és XIII-as faktort tartalmaz | |
BG106030A (en) | Pharmaceutical composition | |
HUP0003784A2 (hu) | Fájdalmas menstruáció és koraszülés kezelésére alkalmas gyógyászati készítmény | |
BRPI0308663B8 (pt) | uso de inibidores de il-18 para o tratamento e/ou prevenção de doenças vasculares periféricas | |
MA26882A1 (fr) | COMPOSITIONS PHARMACEUTIQUES D'INHIBITEURS ET GLYCOGèNE-PHOSPHORYLASE | |
IS2789B (is) | Lyfjablöndur sem innihalda mónóamínoxídasa B hemla | |
BR0110506A (pt) | Uso de inibidores de il-18 para o tratamento e/ou prevenção da aterosclerose | |
ATE219061T1 (de) | Huperzin a analoge verbindungen | |
HUP0004544A2 (hu) | Angiotenzin-átalakító enzim inhibitora és diuretikum kombinációjának alkalmazása mikrokeringési rendellenességek kezelésére szolgáló gyógyászati készítmény előállítására | |
ATE308328T1 (de) | Pharmazeutische zusammensetzung enthaltend clindamycin und clotrimazol, zur behandlung vaginaler infektionen | |
HUP0400553A2 (hu) | Gyógyászati készítmények | |
DK1069902T3 (da) | Anvendelse af phospholipider til fremstilling af et lægemiddel til forebyggelse af adhæsioner | |
AR015966A1 (es) | Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito | |
CA2417935A1 (en) | Anti-inflammatory medicament | |
UA90249C2 (uk) | Комбінація, що містить кандесартан та розувастатин, фармацевтична композиція, яка її містить, та застосування | |
IL141515A (en) | Optically active pyridyl- 4h - 1, 2, 4 - oxadiazine derivative and its use in the treatment of vascular diseases and pharmaceutical composition comprising same | |
HUP0203226A2 (hu) | Hatóanyagként benzamidszármazékot tartalmazó gyógyszerkészítmény | |
SE0001916D0 (sv) | Novel formulation | |
MY121604A (en) | Combination therapy for hiv infection using the hiv protease inhibitor indinavir and the reverse transcriptase inhibitor 3tc together with azt | |
SE9902937D0 (sv) | Pharmaceutical compositions |